Daratumumab (Dara), Cyclophosphamide, Thalidomide and Dexamethasone for Transplant Eligible Newly Diagnosed Multiple Myeloma (TE NDMM) Patients: Response Rate Impacts on PFS

被引：0

作者：

Crusoe, Edvan De Queiroz ^{[1
,2
,3
]}

Leal, Joanna ^{[4
]}

Santos, Juliana Andrade ^{[5
,6
]}

de Melo Santos, Herbert Henrique ^{[7
]}

Santos, Allan de Souza ^{[7
]}

Lucas, Larissa Ferreira ^{[6
]}

Almeida, Alessandro de M. ^{[8
,9
]}

Chaves, Marcos ^{[10
]}

Dutra, Daniela Dourado ^{[5
]}

Hungria, Vania T. M. ^{[11
,12
]}

Salvino, Marco Aurelio ^{[2
,13
]}

Arruda, Maria da Gloria B. ^{[6
]}

机构：

[1] Univ Fed Bahia Hosp Univ, Rua Dra Doutro Vianna S-n, Salvador, BA, Brazil

[2] Hosp Univ Prof Edgard Santos Fed Univ Bahia HUPES, Salvador, BA, Brazil

[3] Clin CEHON Rede Dor Oncol, Hematol Dept Dor Oncol, Salvador, BA, Brazil

[4] Hematol Rede Dor Oncol, Hematol, Salvador, BA, Brazil

[5] Univ Fed Bahia, Salvador, BA, Brazil

[6] CLin CEHON Rede Dor Oncol, Hematol, Salvador, BA, Brazil

[7] Univ Fed Bahia, Immunol Mol & Cytometry Lab ICS, Salvador, BA, Brazil

[8] Univ Fed Bahia, Stem Cell Transplant Unit, Salvador, BA, Brazil

[9] Rede Dor Oncol, Hematol & Bone Marrow Unit, Salvador, BA, Brazil

[10] Fed Univ Bahia Hematol & Hemotheraphy, Salvador, BA, Brazil

[11] Santa Casa Med Sch, Hematol, Sao Paulo, Brazil

[12] Clin Sao Germano, Dept Hematol & Oncol, Sao Paulo, Brazil

[13] Rede Dor Oncol, Hematol & Bone Marrow Transplantat UNIT, Salvador, BA, Brazil

来源：

BLOOD | 2022年 / 140卷

关键词：

D O I：

10.1182/blood-2022-164866

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：7699 / 7700

页数：2

共 50 条

[11] Daratumumab (DARA) plus Bortezomib/ Thalidomide/Dexamethasone (D-VTd) Followed by DARA Maintenance in Transplant-eligible (TE) Newly Diagnosed Multiple Myeloma (NDMM): >6-Year Update of the Phase 3 CASSIOPEIA Study
Moreau, Philippe
Hulin, Cyrille
Perrot, Aurore
Arnulf, Bertrand
Belhadj, Karim
Benboubker, Lotfi
Zweegman, Sonja
Caillon, Helene
Caillot, Denis
Avet-Loiseau, Herve
Delforge, Michel
Dejoie, Thomas
Facon, Thierry
Sonntag, Cecile
Fontan, Jean
Mohty, Mohamad
Jie, Kon-Siong
Karlin, Lionel
Kuhnowski, Frederique
Lambert, Jerome
Leleu, Xavier
Macro, Margaret
Orsini-Piocelle, Frederique
Roussel, Murielle
de Colella, Jean Marc Schiano
van de Donk, Niels W. C. J.
Wuilleme, Soraya
Broijl, Annemiek
Touzeau, Cyrille
Tiab, Mourad
Marolleau, Jean-Pierre
Meuleman, Nathalie
Vekemans, Marie-Christiane
Westerman, Matthijs
Klein, Saskia K.
Levin, Mark-David
Offner, Fritz
Escoffre-Barbe, Martine
Eveillard, Jean-Richard
Garidi, Reda
Hua, Winnie
Wang, Jianping
Tuozzo, Alba
de Boer, Carla J.
Rowe, Melissa
Vanquickelberghe, Veronique
Carson, Robin
Vermeulen, Jessica
Corre, Jill
Sonneveld, Pieter
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S560 - S561
[12] Effect of Daratumumab (DARA), Cyclophosphamide (C), T Halidomide (T) and Dexamethasone (D) combination of Lymphocyte populations of transplant eligible newly diagnosed Multiple Myeloma patients
Santos, Allan
Santos, Herbert
Salvino, Marco
Santos, Juliana
Queiroz, Sarah
Lucas, Larissa
Almeida, Alessandro
Santos, Mariane
Leal, JOanna
Arruda, Maria da Gloria
Torres, Alex
Crusoe, Edvan
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S75 - S75
[13] Depth of Response to Daratumumab (DARA), Lenalidomide, Bortezomib, and Dexamethasone (RVd) Improves over Time in Patients (pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Griffin Study Update
Voorhees, Peter M.
Kaufman, Jonathan L.
Laubach, Jacob P.
Sborov, Douglas W.
Reeves, Brandi
Rodriguez, Cesar
Chari, Ajai
Silbermann, Rebecca W.
Costa, Luciano J.
Anderson, Larry D.
Nathwani, Nitya
Shah, Nina D.
Efebera, Yvonne A.
Costello, Caitlin L.
Jakubowiak, Andrzej
Wildes, Tanya M.
Orlowski, Robert Z.
Shain, Kenneth H.
Cowan, Andrew J.
Murphy, Sean
Lutska, Yana
Pei, Huiling
Ukropec, Jon
Vermeulen, Jessica
de Boer, Carla
Hoehn, Daniela
Lin, Thomas S.
Richardson, Paul G.
BLOOD, 2019, 134
[14] Daratumumab (DARA) plus bortezomib/lenalidomide/dexamethasone (VRd) in transplant-eligible (TE) patients (pts) with newly diagnosed multiple myeloma (NDMM): Analysis of minimal residual disease (MRD) in the PERSEUS trial.
Rodriguez-Otero, Paula
Moreau, Philippe
Dimopoulos, Meletios Athanasios
Beksac, Meral
Perrot, Aurore
Broijl, Annemiek
Gay, Francesca
Mina, Roberto
van de Donk, Niels W. C. J.
Schjesvold, Fredrik
Delforge, Michel
Einsele, Hermann
Spencer, Andrew
Lonergan, Sarah
Vieyra, Diego
Sitthi-Amorn, Anna
Carson, Robin L.
Blade, Joan
Boccadoro, Mario
Sonneveld, Pieter
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[15] Daratumumab (DARA) with Bortezomib, Thalidomide, and Dexamethasone (VTd) in Transplant-Eligible Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM): Analysis of Minimal Residual Disease (MRD) Negativity in Cassiopeia Part 1 and Part 2
Loiseau, Herve Avet
Sonneveld, Pieter
Moreau, Philippe
Offner, Fritz
van der Velden, Vincent H. J.
Caillot, Denis
Hulin, Cyrille
Arnulf, Bertrand
Corre, Jill
Mohty, Mohamad
Karlin, Lionel
Lambert, Jerome
Macro, Margaret
Perrot, Aurore
Levin, Mark-David
Klein, Saskia K.
Stoppa, Anne-Marie
Delforge, Michel
Zweegman, Sonja
Jie, Kon-Siong
Van De Donk, Niels W. C. J.
Krevvata, Maria
Rigat, Fabio
Yang, Shiyi
Vanquickelberghe, Veronique
de Boer, Carla
Kampfenkel, Tobias
Vermeulen, Jessica
Wuilleme, Soraya
Broyl, Annemiek
Bene, Marie C.
BLOOD, 2021, 138
[16] Daratumumab (DARA) plus Lenalidomide/Bortezomib/Dexamethasone (RVd) in African American/Black Patients (Pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Subgroup Analysis of GRIFFIN
Nooka, Ajay K.
Kaufman, Jonathan L.
Rodriguez, Cesar
Jakubowiak, Andrzej
Shune, Leyla
Badros, Ashraf
Chari, Ajai
Richardson, Paul G.
Pei, Huiling
Ukropec, Jon
Vermeulen, Jessica
Hoehn, Daniela
Lin, Thomas S.
Voorhees, Peter M.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S308 - S309
[17] Efficacy of daratumumab (DARA) plus bortezomib/thalidomide/dexamethasone (D-VTd) in transplant-eligible newly diagnosed multiple myeloma (TE NDMM) based on minimal residual disease (MRD) status: Analysis of the CASSIOPEIA trial.
Avet-Loiseau, Herve
Moreau, Philippe
Attal, Michel
Hulin, Cyrille
Arnulf, Bertrand
Corre, Jill
Garderet, Laurent
Karlin, Lionel
Lambert, Jerome
Macro, Margaret
Perrot, Aurore
Sonneveld, Pieter
Levin, Mark-David
Klein, Saskia
Chiu, Christopher
Pei, Lixia
De Boer, Carla
Kampfenkel, Tobias
Wuilleme, Soraya
Bene, Marie-Christine
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[18] Response and survival outcomes of daratumumab, lenalidomide, bortezomib and dexamethasone (D-RVD) induction in transplant-eligible newly diagnosed multiple myeloma (NDMM) patients
Joseph, Nisha
Kaufman, Jonathan
Lonial, Sagar
Hofmeister, Craig
Dhodapkar, Madhav
Gupta, Vikas
DiCamillo, Sara
Roberts, Danielle
Boise, Lawrence
Nooka, Ajay
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S113 - S113
[19] Bortezomib, thalidomide, and dexamethasone with or without daratumumab for transplantation-eligible patients with newly diagnosed multiple myeloma (CASSIOPEIA)
Roussel, Murielle
Moreau, Philippe
Hebraud, Benjamin
Laribi, Kamel
Jaccard, Arnaud
Dib, Mamoun
Slama, Borhane
Dorvaux, Veronique
Royer, Bruno
Frenzel, Laurent
Zweegman, Sonja
Klein, Saskia K.
Broijl, Annemiek
Jie, Kon-Siong
Wang, Jianping
Vanquickelberghe, Veronique
Boer, Carla de
Kampfenkel, Tobias
Gries, Katharine S.
Fastenau, John
Sonneveld, Pieter
LANCET HAEMATOLOGY, 2020, 7 (12): : E874 - E883
[20] Phase 3 randomized study of daratumumab (DARA) plus bortezomib/thalidomide/dexamethasone (D-VTd) vs VTd in transplant-eligible (TE) newly diagnosed multiple myeloma (NDMM): CASSIOPEIA Part 1 results.
Moreau, Philippe
Attal, Michel
Hulin, Cyrille
Bene, Marie-Christine
Broijl, Annemiek
Caillot, Denis
Delforge, Michel
Dejoie, Thomas
Facon, Thierry
Lambert, Jerome
Leleu, Xavier
Macro, Margaret
Perrot, Aurore
Zweegman, Sonja
Ahmadi, Tahamtan
Chiu, Christopher
Pei, Lixia
Vermeulen, Jessica
Avet-Loiseau, Herve
Sonneveld, Pieter
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)

← 1 2 3 4 5 →